The discovery and development of sorafenib for the treatment of thyroid cancer.
作者： Peter T White , Mark S Cohen
DOI: 10.1517/17460441.2015.1006194
关键词: Immunology 、 MAPK/ERK pathway 、 Thyroid cancer 、 Medicine 、 Tyrosine-kinase inhibitor 、 Cancer research 、 Receptor tyrosine kinase 、 MAPK cascade 、 V600E 、 Sorafenib 、 Kinase
摘要: Introduction: Although the prognosis for most differentiated thyroid cancers (DTCs) remains excellent, recurrence and insensitivity to radioactive iodine (RAI) lead therapeutic challenges poorer outcomes. In defining pathogenesis of DTC, multiple genetic alterations have been identified in key pathways focused around receptor tyrosine kinases (RTKs) MAPK cascade. Sorafenib was specifically developed target rapidly accelerated fibrosarcoma (RAF) kinase pathway. It has shown, however, potent inhibition several RTKs, RAF V600E BRAF mutation, gaining FDA approval November 2013 advanced RAI-refractory DTC.Areas covered: The authors provide a review targeted discovery strategy as well preclinical clinical development sorafenib, leading DTC. also some insight into use sorafenib look at important considerations treatment.Expert opinion: Sorafeni...
informahealthcare.com参考文章(73)
Zhaowen Zhu, Raffaele Ciampi, Marina N. Nikiforova, Manoj Gandhi, Yuri E. Nikiforov, Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. The Journal of Clinical Endocrinology and Metabolism. ,vol. 91, pp. 3603- 3610 ,(2006) , 10.1210/JC.2006-1006
Dirk Strumberg, Heike Richly, Ralf A. Hilger, Norbert Schleucher, Sonke Korfee, Mitra Tewes, Markus Faghih, Erich Brendel, Dimitris Voliotis, Claus G. Haase, Brian Schwartz, Ahmad Awada, Rudolf Voigtmann, Max E. Scheulen, Siegfried Seeber, Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors Journal of Clinical Oncology. ,vol. 23, pp. 965- 972 ,(2005) , 10.1200/JCO.2005.06.124
David S. Cooper, Gerard M. Doherty, Bryan R. Haugen, Richard T. Kloos, Stephanie L. Lee, Susan J. Mandel, Ernest L. Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger, Steven I. Sherman, David L. Steward, R. Michael Tuttle, Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer Thyroid. ,vol. 19, pp. 1167- 1214 ,(2009) , 10.1089/THY.2009.0110
Marcia S. Brose, Catherine T. Frenette, Stephen M. Keefe, Stacey M. Stein, Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective Seminars in Oncology. ,vol. 41, pp. S1- S16 ,(2014) , 10.1053/J.SEMINONCOL.2014.01.001
E L Mazzaferri, N Massoll, Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocrine-related Cancer. ,vol. 9, pp. 227- 247 ,(2002) , 10.1677/ERC.0.0090227
T C Schneider, R M Abdulrahman, E P Corssmit, H Morreau, J W A Smit, E Kapiteijn, Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial European Journal of Endocrinology. ,vol. 167, pp. 643- 650 ,(2012) , 10.1530/EJE-12-0405
Paul T.C Wan, Mathew J Garnett, S.Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, Cancer Genome Project, C.Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford, Richard Marais, Mechanism of Activation of the Raf-Erk Signaling Pathway by Oncogenic Mutations of B-Raf Cell. ,vol. 116, pp. 855- 867 ,(2004) , 10.1016/S0092-8674(04)00215-6
Youjin Je, Fabio AB Schutz, Toni K Choueiri, Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials Lancet Oncology. ,vol. 10, pp. 967- 974 ,(2009) , 10.1016/S1470-2045(09)70222-0
Pascaline Boudou‐Rouquette, Stanislas Ropert, Olivier Mir, Romain Coriat, Bertrand Billemont, Michel Tod, Laure Cabanes, Nathalie Franck, Benoit Blanchet, François Goldwasser, Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist. ,vol. 17, pp. 1204- 1212 ,(2012) , 10.1634/THEONCOLOGIST.2011-0439
Nilofer S. Azad, Jeanny B. Aragon-Ching, William L. Dahut, Martin Gutierrez, William D. Figg, Lokesh Jain, Seth M. Steinberg, Maria L. Turner, Elise C. Kohn, Heidi H. Kong, Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clinical Cancer Research. ,vol. 15, pp. 1411- 1416 ,(2009) , 10.1158/1078-0432.CCR-08-1141